title: [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension].
abstract: OBJECTIVE
  To evaluate the therapeutic value of latanoprost on glaucoma.
  
  
  METHODS
  In an open-label fashion, multicenter, randomized control clinical trial, the efficacy and adverse drug reactions of topical application of 0.005% latanoprost once daily were compared with that of 0.5% timolol twice daily for 12 weeks in patients with open-angle glaucoma or ocular hypertension.
  
  
  RESULTS
  The study included 128 patients (63 patients in latanoprost group and 65 patients in timolol group) and 117 patients remained at the end of the study (60 cases in latanoprost group and 57 cases in timolol group). Comparing 12 weeks with baseline diurnal intraocular pressure (IOP), the IOP reduction (mean +/- standard deviation) in latanoprost group was (7.5 +/- 0.3) mm Hg (1 mm Hg = 0.133 kPa) (32%, t = 22.73, P < 0.0001) greater than the reduction in timolol group (6.1 +/- 0.3) mm Hg (26%, t = 17.94, P < 0.0001), the difference between the two groups being significant (F = 9.54, P = 0.0026). Two patients treated with timolol and none treated with latanoprost were withdrawn from the study because of inadequate IOP control; 3 patients with latanoprost had foreign body sensation. In latanoprost group, there was one patient whose eyelashes became darker and longer at the last visit (the 12th week). No ocular and systemic adverse events related to the two drugs were found.
  
  
  CONCLUSIONS
  It is demonstrated that 0.005% latanoprost topically applied once daily is well tolerated and more effective in reducing IOP than 0.5% timolol topically applied twice daily. Thus, latanoprost has the potential to be a new first-line antiglaucoma drug.
authors.affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
authors.forename: D
authors.initials: D
authors.lastname: Peng
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Shao
authors.forename: X
authors.initials: X
authors.lastname: Sun
authors.forename: Y
authors.initials: Y
authors.lastname: Sheng
authors.forename: K
authors.initials: K
authors.lastname: Yu
authors.forename: P
authors.initials: P
authors.lastname: Fu
authors.forename: W
authors.initials: W
authors.lastname: Guo
authors.forename: F
authors.initials: F
authors.lastname: Meng
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.forename: Z
authors.initials: Z
authors.lastname: Zhu
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D013999:Timolol / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol